Intro: An evidence-based article — using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management.
01 Start with an underestimated fact: Fatty liver is not “suboptimal health”
It has already become the most common chronic liver disease.
Many people still think of fatty liver as “a negligible arrow on a health checkup report.” But global authoritative data and the latest nomenclature have long redefined it as an epidemic:
According to a 2024 epidemiological review by Younossi et al. published in Clinical Gastroenterology and Hepatology, approximately 38% of adults worldwide have metabolic dysfunction-associated steatotic liver disease (MASLD), with a prevalence of 7%–14% among children and adolescents [1].
In China, a meta-analysis incorporating 561 studies and covering 6.63 million people showed that the prevalence of MASLD in adults is as high as 30.4%, and it continues to rise — 27.6% before 2010, 31.7% during 2015–2019, and surging to 36.5% after 2019 [2].
More critical is its “silent” nature: fatty liver causes no pain and goes unnoticed until it progresses to MASH (metabolic dysfunction-associated steatohepatitis) and liver fibrosis, eventually leading to cirrhosis and liver cancer.
The global scale of overweight and obesity provides the underlying logic for these numbers:
- World Health Organization (WHO) 2022 data showed 2.5 billion adults were overweight, of whom 890 million were obese; by 2024, the global obese population had exceeded 1 billion [3][4].
- The China Nutrition and Chronic Disease Status Report (2020) showed that 34.3% of adults were overweight and 16.4% were obese — a combined total exceeding 50%, meaning one in two adults is overweight or obese [5].
- The 2026 Chinese Obesity Guidelines updated this figure: in 2024, China’s overweight/obesity prevalence had reached 56.4%, projected to reach 70.5% (approximately 611 million people) by 2030 [19].
- The Lancet Global Burden of Disease Study noted that China has 402 million overweight and obese adults, ranking first in the world [6].
The conclusion is straightforward:
Fatty liver is the leading chronic liver disease in China, and its “fuel” — obesity and metabolic disorders — is still accelerating.
02 Evidence-based medicine: Why are guidelines and the FDA all emphasizing “quantitative monitoring of liver fat”?
If epidemiological data proves that “there are enough people,” the next question is: why do these people need “continuous, quantitative” liver fat monitoring, rather than just a blood test once a year? The answer lies in several recent authoritative documents.
How much weight loss is needed for liver fat to truly decrease? — The 2024 Joint Guidelines by Three European Societies give hard metrics
The 2024 MASLD Clinical Practice Guidelines jointly issued by the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) provide a widely cited “dose-response” relationship:
Weight loss ≥5% reduces hepatic steatosis; 7%–10% improves inflammation; ≥10% may improve liver fibrosis [7].
The clinical implication of this statement is: whether weight loss “works” and “to what extent” must be answered through quantitative liver fat measurement. The scale only tells you “how many kilograms you’ve lost,” but cannot answer “how much liver fat has actually decreased” — and the latter is the key to determining how far you are from cirrhosis.
Clinical studies confirm this: a study published in the Journal of Clinical Investigation showed that with approximately 10% weight loss, intrahepatic triglyceride content (IHTG) decreased from 19.4% to 4.5% (P < 0.001) [8].
China 2026 Guidelines: Quantitative liver fat officially written into obesity diagnostic criteria
In August 2026, the Chinese Society of Endocrinology of the Chinese Medical Association issued the Guidelines for Long-Term Weight Management and Clinical Application of Pharmacotherapy in Patients with Obesity (2026 Edition). In Table 2 — “Common Diagnostic Criteria for Obesity in the Chinese Population” — it explicitly lists “liver fat content” as one of the indicators for obesity diagnosis, with quantitative grading standards [19]:
| Detection Method | Grading Criteria |
|---|---|
| Ultrasound Attenuation Parameter (CAP value) | Normal: <248 dB/m; Significant hepatic steatosis: ≥248 dB/m; Moderate-severe hepatic steatosis: ≥268 dB/m; Severe hepatic steatosis: ≥294 dB/m |
| MRI-PDFF | Normal: <5%; Mild hepatic steatosis: 5%–10%; Moderate: 10%–25%; Severe: >25% |
This means that within the latest Chinese official diagnostic framework, “how much fat is in the liver” has become a quantifiable indicator for judging obesity and its severity, alongside body weight, waist circumference, and body fat percentage.
FDA milestone: GLP-1 officially approved for liver disease — “monitoring” becomes a necessary step in medication use
On August 15, 2025, the U.S. FDA approved Wegovy (semaglutide 2.4 mg) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-severe liver fibrosis (F2–F3) — making it the first GLP-1 receptor agonist approved globally for liver disease, and the second MASH treatment approved after resmetirom [9].
Three details from this approval directly point to the clinical necessity of “liver fat monitoring”:
- The indication is built upon quantitative imaging assessment: The supporting Phase 3 ESSENCE trial used imaging metrics (MRI-PDFF, etc.) and histological endpoints to quantify improvements in liver fat and fibrosis [9].
- ESSENCE trial results: At 72 weeks, 63% of patients in the semaglutide group achieved MASH resolution without worsening of fibrosis, compared to only 34% in the placebo group [10].
- Accelerated approval = ongoing monitoring required: Because the approval followed the “surrogate endpoint” accelerated pathway, regulators require continued post-marketing data collection on clinical benefit — meaning every patient starting therapy needs a quantifiable liver fat baseline and ongoing follow-up assessments.
The American Association for the Study of Liver Diseases (AASLD) subsequently issued a dedicated practice update on semaglutide for MASLD/MASH in November 2025, explicitly requiring monitoring of treatment safety and efficacy [11].
Guidelines endorse “monitoring” — MRI-PDFF is the gold standard, but its cost and accessibility create a gap
The AASLD 2024 Imaging-Based Noninvasive Assessment Guidelines and the EASL 2024 Guidelines consistently confirm:
- MRI-PDFF (proton density fat fraction) is the “gold standard” for non-invasive quantitative liver fat measurement, suitable for grading and monitoring treatment response [7][12].
- But it is expensive, reliant on large equipment, and has long appointment wait times — making it unsuitable for high-frequency, continuous, or decentralized monitoring scenarios.
- While technologies like the Controlled Attenuation Parameter (CAP) are non-invasive, the AASLD Guidelines also explicitly note that CAP cannot accurately quantify or continuously monitor changes in liver fat [13].
This creates a clear structural gap: guidelines demand “continuous, quantitative” monitoring of liver fat, but the tools that meet this requirement (MRI-PDFF) are both expensive and inaccessible.
03 Market reality: GLP-1 weight-loss drugs are exploding at a visible pace
Monitoring demand does not emerge from nowhere — it is being “fed” by an already-validated, high-growth industrial chain.
Global: $132 billion — and still accelerating
According to data released at the 2026 AMCP Annual Meeting, global GLP-1 drug sales reached approximately $132 billion in 2025, with year-over-year growth of 33.5% [14]:
| Drug | 2025 Sales | YoY Growth |
|---|---|---|
| Mounjaro (tirzepatide, diabetes) | $39.1B | +67.1% |
| Zepbound (tirzepatide, weight loss) | $22.9B | +188.7% |
| Wegovy (semaglutide, weight loss) | $18.6B | +29.2% |
The weight-loss indication is the fastest-growing segment. Grand View Research projects the global GLP-1 weight-loss drug market will grow from $13.8 billion in 2024 to **$48.8 billion by 2030** (CAGR 18.5%) [15]. J.P. Morgan estimates that by 2030, approximately 25 million people in the U.S. alone will be using GLP-1 drugs (up from ~10 million in 2025) [16].
China: Penetration rate only ~1% — the largest gap and fastest growth
The Chinese market shows a classic pattern of “low penetration, high growth”:
- Global GLP-1 drug sales exceeded **$50 billion** in 2024, with semaglutide alone contributing ~$25 billion and tirzepatide ~$16 billion [17].
- According to China Industrial Research data, China’s GLP-1 weight-loss drug market is expected to exceed ¥15 billion in 2025, with penetration projected to rise from less than 5% in 2023 to 18%–20% [17].
- More noteworthy is a striking comparison: China’s adult obesity rate is 16.4% and overweight rate 34.3%, but GLP-1 penetration among the obese population is only about 1% [18].
Medication users are precisely the population that most needs “liver fat monitoring”
GLP-1 users and the high-risk population for fatty liver heavily overlap — most are overweight or obese, with underlying metabolic disorders. Weight-loss drugs reduce body weight while also changing liver fat; but “how much has it changed” can only be known through quantitative monitoring.
- Guidelines demand: ≥5% weight loss to reduce steatosis, ≥10% to possibly improve fibrosis [7] — without quantitative monitoring, you don’t know which tier you’re in.
- Real-world pain points: scales, body fat analyzers, and ALT blood tests cannot directly reflect liver fat. And MRI-PDFF is both expensive and difficult to schedule.
“GLP-1 + liver fat monitoring” is becoming a new essential combination jointly driven by global guidelines and the FDA.
04 Conclusion
From epidemiological data showing “hundreds of millions affected,” to the 2026 Chinese Guidelines writing quantitative liver fat into diagnostic criteria, to the FDA embedding monitoring into the GLP-1 liver disease treatment pathway — “quantitative liver fat monitoring” is transitioning from optional to standard practice.
The bottleneck to implementation has always been the gap between “gold-standard capability” and “high-frequency, accessible, decentralized deployment.” How to close this gap is the challenge that the entire industry will need to address together.
References
[1] Younossi ZM, et al. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2024. https://pubmed.ncbi.nlm.nih.gov/39159948/
[2] Meta-analysis of MASLD prevalence in Chinese adults (561 studies, 6.63 million people). MedSci. https://nursing.medsci.cn/article/show_article.do?id=5e9e925e5784
[3] WHO. Obesity and overweight — Fact sheet. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[4] World Obesity Federation / NCD-RisC. Prevalence of obesity. https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity
[5] China Nutrition and Chronic Disease Status Report (2020). China Youth Net. https://news.youth.cn/jswx/202405/t20240516_15256033.htm
[6] Lancet Global Burden of Disease Study (2021). Chinese CDC. https://literature.chinacdc.cn/xuekefuwu/gonggongweishengxueshuredianzhuz/202503/t20250311_304818.html
[7] EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol. 2024;81:492-542. https://karger.com/ofa/article/17/4/374/908875/EASL-EASD-EASO-Clinical-Practice-Guidelines-on-the
[8] Weight loss of 10% reduces IHTG from 19.4% to 4.5%. J Clin Invest. https://www.jci.org/articles/view/174233
[9] FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’ (Wegovy approval). https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
[10] Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392:2089-2099. https://www.pharmacytimes.com/view/semaglutide-receives-fda-approval-for-treatment-of-mash
[11] Semaglutide therapy for MASH: November 2025 updates to AASLD Practice Guidance. https://pubmed.ncbi.nlm.nih.gov/41201884/
[12] AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2024. https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000000843
[13] AASLD Practice Guidance on the clinical assessment and management of NAFLD. https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/
[14] GLP-1 drugs to drive growth (AMCP 2026). Managed Healthcare Executive. https://www.managedhealthcareexecutive.com/view/glp-1-drugs-to-drive-growth-in-obesity-and-diabetes-treatment-amcp-annual-2026
[15] GLP-1 Agonists Weight Loss Drugs Market Report. Grand View Research. https://www.grandviewresearch.com/industry-analysis/glp-1-agonists-weight-loss-drugs-market-report
[16] J.P. Morgan. How Supply and Demand for Weight Loss Drugs is Playing Out in 2026. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
[17] Semaglutide faces new competitors. Beijing News. https://m.bjnews.com.cn/detail/1751333560168858.html
[18] Price cuts on semaglutide and tirzepatide. Cailianshe. https://www.cls.cn/detail/2241765
[19] Guidelines for Long-Term Weight Management and Clinical Application of Pharmacotherapy in Patients with Obesity (2026 Edition). Chinese Society of Endocrinology, Chinese Medical Association. Chinese Journal of Endocrinology and Metabolism, August 2026, Vol. 42, No. 8.
Eieling Technology
Liver health, at your side
- Named to Forbes “Asia-Pacific 100 Companies to Watch” in 2023
- CES 2026 Digital Health Innovation Award Winner
📞 +86 156 0176 5936
🌏 www.eieling.com
✉ info@eieling.com